TARVEDA THERAPEUTICS
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.
TARVEDA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics Medical Therapeutics
Founded:
2012-01-01
Address:
Watertown, Massachusetts, United States
Country:
United States
Website Url:
http://www.tarvedatx.com
Total Employee:
11+
Status:
Closed
Contact:
(617)923-4100
Email Addresses:
[email protected]
Total Funding:
148.43 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Amazon SSL By Default AWS Global Accelerator OpenResty GoDaddy SSL Google Adsense AdBlock Acceptable Ads GoDaddy CDN
Similar Organizations
Candel Therapeutics
Candel Therapeutics develops cancer immunotherapies designed to improve the lives of cancer patients and their families.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Exact Sciences
Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
Fio
Fio is a developer of a point-of-care medical device used to gather data through interactions with a healthcare system.
Prevencio
Prevencio is a developer of multi-proteomic biomarkers designed to revolutionize blood tests for cardiovascular disease.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Sight Sciences
Sight Sciences is a medical device company that uses a computer-based device designed for the treatment of eye disease.
Tessa Therapeutics
Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors.
Vesalius Therapeutics
Vesalius Therapeutics is focused on redefining the understanding and treatment of the diseases that drive ninety percent of human illness.
Current Advisors List
Current Employees Featured
Founder
Investors List
Novo Holdings
Novo Holdings investment in Series D - Tarveda Therapeutics
Versant Ventures
Versant Ventures investment in Series D - Tarveda Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series D - Tarveda Therapeutics
Flagship Pioneering
Flagship Pioneering investment in Series D - Tarveda Therapeutics
+ND Capital
+ND Capital investment in Series D - Tarveda Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series C - Tarveda Therapeutics
Novo Holdings
Novo Holdings investment in Series C - Tarveda Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series B - Tarveda Therapeutics
+ND Capital
+ND Capital investment in Series B - Tarveda Therapeutics
Eminent Venture Capital
Eminent Venture Capital investment in Series B - Tarveda Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2020-09-30 | Tarveda Therapeutics Appoints Brian Roberts as Chief Executive Officer |
Official Site Inspections
http://www.tarvedatx.com
- Host name: 104.21.59.9
- IP address: 104.21.59.9
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Tarveda Therapeutics"
Tarveda Therapeutics - LinkedIn
Tarveda Therapeutics | 2,282 followers on LinkedIn. To discover, develop and commercialize a new class of potent and selective precision oncology medicines. | Tarveda Therapeutics is a clinical ...See details»
Tarveda Therapeutics, Inc - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Tarveda Therapeutics, Inc of Watertown, MA. Get the latest business insights from Dun & Bradstreet.See details»
Tarveda Therapeutics - Crunchbase Company Profile & Funding
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate …See details»
Tarveda Therapeutics Company Overview, Contact Details
Sep 29, 2020 | www.tarvedatx.com Tarveda Therapeutics, Inc. is developing HSP90 binding miniature drug conjugate platform. In addition to PEN-866, Tarveda is developing additional …See details»
Tarveda Therapeutics - Company Profile - Tracxn
4 days ago Tarveda Therapeutics - Developer of small molecule therapeutics for the treatment of cancer. Raised a total funding of $119M over 6 rounds from 6 investors. Founded by Stephen …See details»
Organovo and Tarveda Therapeutics Announce Definitive Merger …
Dec 16, 2019 Management and Organization. Following the merger, the combined company will be led by the current Tarveda management team, including Drew Fromkin as President, Chief …See details»
Tarveda Therapeutics - Craft
See insights on Tarveda Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Tarveda Therapeutics - Overview, News & Similar companies
Nov 1, 2021 www.tarvedatx.com. Revenue $8.4 Million. Industry Business Services General Business Services . Recent News & Media. Organovo Says No to Tarveda Merger. Apr 18, …See details»
Tarveda Therapeutics Appoints Brian Roberts as Chief …
Sep 30, 2020 Prior to Insulet, Mr. Roberts served as Chief Financial Officer for Jingle Networks, which was acquired by Marchex, Inc. Mr. Roberts also served as Chief Financial Officer at Digitas, where he was ...See details»
Tarveda Therapeutics Email Formats & Email Address Examples
Tarveda Therapeutics Email Format . Biotechnology Research Massachusetts, United States 11-50 Employees. Tarveda Therapeutics is a clinical stage biopharmaceutical company …See details»
Tarveda Therapeutics Presents Promising Phase 2 Data …
Jun 4, 2021 Results presented at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting PEN-221 to be further evaluated in a randomized trial in patients with gastrointestinal neuroendocrine tumorsSee details»
Tarveda Therapeutics CEO and Key Executive Team | Craft.co
Tarveda Therapeutics's President, CEO, Director is Brian Roberts. Other executives include Dennis Ausiello, Director; Karen Hong, Director. See the full leadership team at Craft.See details»
Tarveda Therapeutics Announces Data from Phase 2 Trial of
Nov 1, 2021 WATERTOWN, Mass.--(BUSINESS WIRE)-- Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision …See details»
Tarveda Therapeutics to Present Data from Phase 2 Study of PEN …
May 20, 2021 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to …See details»
Targeting the Somatostatin Receptor 2 with the Miniaturized Drug ...
1 Tarveda Therapeutics Inc., Watertown, Massachusetts. [email protected]. 2 Tarveda Therapeutics Inc., Watertown, Massachusetts. PMID: 31649014; DOI: 10.1158/1535 …See details»
Tarveda Therapeutics Provides Update on Proposed Merger with
Apr 7, 2020 Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to …See details»
Tarveda Therapeutics and SciClone Pharmaceuticals Expand …
Sep 16, 2021 WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and …See details»
Tarveda Therapeutics Provides Update on Proposed Merger with
Apr 7, 2020 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as …See details»
Tarveda Therapeutics Announces Data from Phase 2 Trial
Nov 1, 2021 WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision …See details»
Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 ...
Aug 4, 2020 Study published in Molecular Cancer Therapeutics. HSP90 targeting drives high tumor uptake and retention of a pan-PI3K inhibitor payload. Lead conjugate shows xenograft …See details»